Biosimilars: What clinicians should know

Blood

Volumn 120, Issue 26, 2012, Pages 5111-5117

  Weise, Martina ^a   Bielsky, Marie Christine ^b   De Smet, Karen ^c   Ehmann, Falk ^d   Ekman, Niklas ^e   Giezen, Thijs J ^f   Gravanis, Iordanis ^d   Heim, Hans Karl ^a   Heinonen, Esa ^e   Ho, Kowid ^g   Moreau, Alexandre ^g   Narayanan, Gopalan ^b   Kruse, Nanna A ^h   Reichmann, Gabriele ⁱ   Thorpe, Robin ^j   Van Aerts, Leon ^k   Vleminckx, Camille ^d   Wadhwa, Meenu ^j   Schneider, Christian K ^h,l  

^a Bundesinstitut fur Arzneimittel und Medizinproducte   (Germany)

^b MEDICINES AND HEALTHCARE PRODUCTS REGULATORY AGENCY   (United Kingdom)

^c Federal Agency for Medicines and Health Products Belgium   (Belgium)

^d EUROPEAN MEDICINES AGENCY   (United Kingdom)

^e Finnish Medicines Agency   (Finland)

^f MEDISCH SPECTRUM TWENTE   (Netherlands)

^g Agence Nationale de Securité du Médicament et des Produits de Santé ANSM   (France)

^h Danish Health and Medicines Authority   (Denmark)

ⁱ PAUL EHRLICH INSTITUT   (Germany)

^j NATIONAL INSTITUTE FOR BIOLOGICAL STANDARDS AND CONTROL   (United Kingdom)

^k MEDICINES EVALUATION BOARD   (Netherlands)

^l INSTITUTE OF INFECTION IMMUNOLOGY   (Germany)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BIOSIMILAR AGENT; ERYTHROPOIETIN; GLUCOSE; GRANULOCYTE COLONY STIMULATING FACTOR; HUMAN GROWTH HORMONE; MONOCLONAL ANTIBODY; RECOMBINANT ERYTHROPOIETIN; SOMATOMEDIN C;

AMINO ACID SEQUENCE; CONSULTATION; DRUG EFFICACY; DRUG QUALITY; DRUG SAFETY; FERTILIZATION IN VITRO; HEALTH CARE COST; HUMAN; IMMUNOGENICITY; NEUTROPHIL COUNT; OOCYTE RETRIEVAL; OVERALL SURVIVAL; PHYSICAL CHEMISTRY; PHYSICIAN; PRIORITY JOURNAL; REVIEW; STEM CELL MOBILIZATION;

EID: 84871492817     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2012-04-425744     Document Type: Review

References (48)

1. European Medicines Agency. European Assessment Reports for authorised medicinal products for human use. http://www.ema.europa.eu/ema/index.jsp?curl= pages/medicines/landing/epar-search.jsp&murl=menus/medicines/medicines. jsp&mid=WC0b01ac058001d125. Accessed October 20, 2012.
2. European Medicines Agency. Applications for new human medicines under evaluation by the Committee for Medicinal Products for Human Use, April 2012. http://www.ema.europa.eu/docs/en-GB/document-library/Report/2012/04/WC500125365. pdf. Accessed October 20, 2012.
3. European Medicines Agency, Committee for Medicinal Products for Human Use. Biosimilar Guidelines. https://www.ema.europa.eu/ema/index.jsp?curl=pages/ regulation/general/general-content-000408.jsp&murl=menus/regulations/ regulations.jsp&mid=WC0b01ac058002958c. Accessed October 20, 2012.
4. Patient Protection and Affordable Care Act, as amended by the 111th Congress, H.R. 3590. http://frwebgate.access.gpo.gov/cgi-bin/getdoc.cgi?dbname= 111-cong-bills&docid=f:h3590enr.txt.pdf. Accessed October 20, 2012.
5. U.S. Food and Drug Administration. Draft guidance on biosimilar product development. http://www.fda.gov/Drugs/DevelopmentApprovalProcess/ HowDrugsareDevelopedandApproved/ApprovalApplications/ TherapeuticBiologicApplications/Biosimilars/default.htm. Accessed October 20, 2012.
6. Minghetti P, Rocco P, Cilurzo F, Vecchio LD, Locatelli F. The regulatory framework of biosimilars in the European Union. Drug Discov Today. 2012;17(1):63-70.
7. European Medicines Agency, Committee for Medicinal Products for Human Use. Guideline on similar biological medicinal products containing biotechnology-derived proteins as active substance: quality issues. http://www.ema.europa.eu/pdfs/human/biosimilar/4934805en.pdf. Accessed October 20, 2012.
8. ICH Guideline topic QE5: Comparability of Biotechnological/Biological Products Subject to Changes in their Manufacturing Process. http://www.ich.org/ products/guidelines/quality/article/quality-guidelines.html. Accessed October 20, 2012.
9. Weise M, Bielsky MC, De Smet K, et al. Biosimilars: why terminology matters. Nat Biotechnol. 2011;29(8):690-693.
10. Brinks V, Hawe A, Basmeleh AHH, et al. Quality of original and biosimilar epoetin products. Pharm Res. 2011;28(2):386-393.
11. European Medicines Agency. European Assessment Report on Binocrit. http://www.ema.europa.eu/docs/en-GB/document-library/EPAR---Scientific- Discussion/human/000725/WC500053615.pdf. Accessed October 20, 2012.
12. Ranke MB. New preparations comprising recombinant human growth hormone: deliberations on the issue of biosimilars. Horm Res. 2008;69(1):22-28. (Pubitemid 350277280)
13. Declerck PJ, Darendeliler F, Goth M, et al. Biosimilars: controversies as illustrated by rhGH. Curr Med Res Opin. 26(5):1219-1229, 2010.
14. Schellekens H. Biosimilar therapeutics: what do we need to consider? NDT Plus. 2009;2(suppl 1):i27-i36.
15. Roger SD. Biosimilars: how similar or dissimilar are they? Nephrology (Carlton). 2006;11(4):341-346. (Pubitemid 44086880)
16. Wadhwa M, Thorpe R. The challenges of immunogenicity in developing biosimilar products. IDrugs. 2009;12(7):440-444.
17. Niederwieser D, Schmitz S. Biosimilar agents in oncology/haematology: from approval to practice. Eur J Haematol. 2011;86(4):277-288.
18. Standing Committee of European Doctors. Position on Access to Medicines: Biosimilars (CPMP 2011/027 Final). http://www.cpme.eu. Accessed August 10, 2012.
19. Dranitsaris G, Amir E, Dorward K. Biosimilars of biological drug therapies. Drugs. 2011;71(12):1527-1536.
20. Seidl A, Hainzl O, Richter M, et al. Tungsten-induced denaturation and aggregation of epoetin alfa during primary packaging as cause of immunogenicity. Pharm Res. 2012;29(6):1454-1467.
21. European Medicines Agency, Committee for Medicinal Products for Human Use. Guideline on immunogenicity assessment of biotechnology-derived therapeutic proteins. https://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/ general/general-content-000408.jsp&murl=menus/regulations/regulations. jsp&mid=WC0b01ac058002958c.Accessed October 20, 2012.
22. European Medicines Agency. European Assessment Report on Omnitrope. http://www.ema.europa.eu/docs/en-GB/document-library/EPAR---Scientific- Discussion/human/000607/WC500043692.pdf. Accessed October 20, 2012.
23. Haag-Weber M, Eckhardt KU, Hörl WH, Roger SD, Vetter A, Roth K. Safety, immunogenicity and efficacy of subcutanteous biosimilar epoetin-α (HX575) in non-dialysis patients with renal anemia: a multi-center, randomized, double-blind study. Clin Nephol. 2012;77(1):8-17.
24. European Medicines Agency. Pharmacovigilance guidelines. http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/document-listing/ document-listing-00199.jsp&murl=menus/regulations/regulations.jsp&mid= WC0b01ac05800250b3. Accessed October 20, 2012.
25. Gastl G, Geissler D, Geissler K, et al. Austrian Society of Hematology and Oncology position on biosimilars. Magazine of European Medical Oncology. 2009;4:232-233.
26. Shaw BE, Confer DL, Hwang WY, Pamphilon DH, Pulsipher MA. Concerns about the use of biosimilar granulocyte colony-stimulating factors for the mobilization of stem cells in normal donors: position of the World Marrow Donor Association. Haematologica. 2011;96(7):942-947.
27. Mellstedt H, Niederwieser D, Ludwig H. The challenge of biosimilars. Ann Oncol. 2008;19(3):411-419. (Pubitemid 351325660)
28. Genazzani AA, Biggio G, Caputi AP, et al. Biosimilar drugs: concerns and opportunities. BioDrugs. 2007;21(6):351-356. (Pubitemid 350145444)
29. World Marrow Donor Association. Concerns about the use of biosimilar granulocyte colony stimulation factors for the mobilization of stem cells in normal donors. http://www.worldmarrow.org/fileadmin/Committees/CLWG/DOC/ 20110706-CLWG-STAT-Biosimilar-abstract.pdf.Accessed October 20, 2012.
30. Barosi G, Bosi A, Abbracchio MP, et al. Key concepts and critical issues on epoetin and filgrastim biosimilars: a position paper from the Italian Society of Hematology, Italian Society of Experimental Hematology, and Italian Group for Bone Marrow Transplantation. Haematologica. 2011;96:937-942.
31. Strober BE, Armour K, Romiti R, et al. Biopharmaceuticals and biosimilars in psoriasis: what the dermatologist needs to know. J Am Acad Dermatol. 2012;66(2):317-322.
32. Russell AS, Ahluwalla V, Barnabe C, et al. Subsequent entry biological/biosimilars: a viewpoint from Canada. Clin Rheumatol. 2012;31(9):1289-1292.
33. American College of Rheumatology. Position statement on biosimilars, January 12, 2010. http://www.rheumatology.org/practice/clinical/position/ biosimilars.pdf#search="biosimilar." Accessed October 20, 2012.
34. European Commission. Directive 2001/83/EC Art. 10(4) and Part II of the Annex I of Directive 2001/83/EC, as amended. EudraLex, Volume 1. Pharmaceutical legislation medicinal products for human use. http://ec.europa.eu/health/ documents/eudralex/vol-1/index-en.htm. Accessed October 20, 2012.
35. Minghetti P, Rocco P, Del Veccio L, Locatelli F. Biosimilars and regulatory authorities. Nephron Clin Pract. 2011;117(1):c1-c7.
36. Jelkmann W. Biosimilar epoetins and other "follow-on" biologics: update on the European experiences. Am J Hematol. 2010;85(19):771-780.
37. European Medicines Agency, Pharmacovigilance Working Party. Monthly report (EMA/816248/2009, issue number 0912). Epoetins: risk of pure red cell aplasia. http://www.ema.europa.eu/pdfs/human/phvwp/81624809en.pdf. Accessed October 20, 2012.
38. European Commission, Public Health. The EU Pharmavigilance System. http://ec.europa.eu/health/human-use/pharmacovigilance/index-en.htm. Accessed October 20, 2012.
39. Covic A, Cannata-Andia J, Cancarini G, et al. Biosimilars and biopharmaceuticals. What the nephrologists need to know: a position paper by the ERA-EDTA Council. Nephrol Dial Transplant. 2008;23(12):3731-3737.
40. Kane A. Fifteen countries have banned automatic substitution of biosimilars: EGA. AMP Health Europe 2008. http://health.apmnews.com/ depechesPublieesDepeches.php?annee=2008&mois=2&jour=21.AccessedAugust 10, 2012.
41. Simoens S. Biosimilar medicines and cost-effectiveness. Clinicoecon Outcomes Res. 2011;3:29-36.
42. Hackbarth GM, Crosson FJ, Miller ME. Report of the Congress: improving incentives in the Medicare program. Washington, DC: Medicare Payment Advisory Commission; 2009.
43. Schneider CK, Kalinke U. Toward biosimilar monoclonal antibodies. Nat Biotechnol. 2008;26(9):985-990.
44. European Medicines Agency, Committee for Medicinal Products for Human Use. Guideline on similar biological medicinal products containing monoclonal antibodies: non-clinical and clinical issues. http://www.ema.europa.eu/docs/en- GB/document-library/Scientific-guideline/2012/06/WC500128686.pdf. Accessed October 20, 2012.
45. Schiestl M, Stangler T, Torella C, Cepeljnik T, Toll H, Grau R. Acceptable changes in quality attributes of glycosylated biopharmaceuticals. Nat Biotechnol. 2011;29(4):310-312.
46. McKoy JM, Stonecash RE, Cournoyer D, et al. Epoetin-associated pure red cell aplasia: past, present, and future considerations. Transfusion. 2008;48(8):1754-1762.
47. European Medicines Agency, Eudravigilance expert working group: Volume 9A: Implementation questions & answers, Version 1.2; February 29, 2008. http://www.ema.europa.eu/pdfs/human/phv/11197208en.pdf. Accessed October 20, 2012.
48. Ebbers HC, Pieters T, Leufkens HG, Schellekens H. Effective pharmaceutical regulation needs alignment with doctors. Drug Discov Today. 2012;17(3):100-103.